Kali Fever
Family · Bloomington, ILNPI 1760764385
Payments from drug & device makers
Across 40 payments — averaging $20.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$201
- LEO Pharma Inc.$113
- Arcutis Biotherapeutics, Inc.$74
- Sun Pharmaceutical Industries Inc.$72
- Incyte Corporation$70
- Novartis$65
- plus $211 from 8 others
What the payments were for
- Food & beverage$70387%
- Education$10413%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 12 | $201 |
| LEO Pharma Inc. | 5 | $113 |
| Arcutis Biotherapeutics, Inc. | 1 | $74 |
| Sun Pharmaceutical Industries Inc. | 3 | $72 |
| Incyte Corporation | 3 | $70 |
| Novartis | 3 | $65 |
| Pfizer | 4 | $61 |
| Johnson & Johnson | 3 | $45 |
| Prism Medical | 1 | $30 |
| Biofrontera Inc. | 1 | $26 |
| Verrica Pharmaceuticals Inc. | 1 | $18 |
| Galderma Laboratories, L.p. | 1 | $15 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $14 |
| Organon | 1 | $1 |
How this compares
$807 in reported general payments places this provider in the 70th percentile of 4,941 family providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cosentyx Sensoready (2 Pens)Secukinumab | 13 | $94,491 |
| Taltz SyringeIxekizumab | 13 | $82,537 |
| Clobetasol Propionate | 62 | $3,981 |
| Fluorouracil | 34 | $2,266 |
| Betamethasone Dipropionate | 45 | $1,812 |
| Betamethasone Valerate | 37 | $1,339 |
| Metronidazole | 26 | $1,175 |
| Triamcinolone Acetonide | 113 | $1,151 |
| Tretinoin | 11 | $1,110 |
| CiclopiroxCiclopirox Olamine | 16 | $1,078 |
| Ketoconazole | 72 | $835 |
| Clindamycin Phosphate | 44 | $819 |
| Doxycycline Hyclate | 25 | $523 |
| Imiquimod | 28 | $497 |
| ValacyclovirValacyclovir Hcl | 20 | $460 |
Paid to pharmacies, not to this prescriber.
Other family in Bloomington
- Brooke KennardBloomington$208K
- Marcella LindstromBloomington$65K
- Ruth CarricoChicago$582K
- Aleksandra BielawiecBarrington$373K
- Erin SieberNaperville$334K
- Jamie BroganChicago$282K
- Ashley NoethGlen Carbon$271K
- Marita KametasChicago$259K
- Shammona ClarkChicago$247K
- Amanda McKeeMount Vernon$242K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.